#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17008	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2553	820.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1686	1686	C	1134	C,T,G	1132,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28658	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3986	896.5	0	.	n	.	0	T695C	SNP	695	695	T	1277	1277	C	1084	C,A,T	1081,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28658	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3986	896.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1919	1919	A	1142	A	1142	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28658	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3986	896.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2553	2553	C	1047	C,T,G	1045,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28658	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3986	896.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2627	2627	A	986	A	986	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28658	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3986	896.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3179	3179	C	1059	C,A,T,G	1055,1,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	28658	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3986	896.5	0	HET	.	.	.	C2839T	.	2839	2839	C	3421	3421	C	1077	C,T	818,255	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2400	folP	852	852	100.0	folP.l15.c4.ctg.1	2110	142.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1299	1301	AGC	232;233;235	A;G;C	232;233;235	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5654	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3842	183.7	1	SNP	p	S91F	0	.	.	271	273	TCC	819	821	TCC	211;212;213	T;C;C	211;212;213	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5654	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3842	183.7	1	SNP	p	D95N	0	.	.	283	285	GAC	831	833	GAC	214;217;214	G;A,C;C	214;216,1;214	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5654	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3842	183.7	1	SNP	p	D95G	0	.	.	283	285	GAC	831	833	GAC	214;217;214	G;A,C;C	214;216,1;214	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2054	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1905	134.7	0	.	p	.	0	A39T	NONSYN	115	117	GCC	746	748	ACC	228;227;225	A;C;C	228;227;225	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2054	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1905	134.7	0	.	p	.	0	R44H	NONSYN	130	132	CGC	761	763	CAC	221;223;220	C;A;C	221;223;220	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2054	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1905	134.7	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	944	946	CAC	286;288;290	C,A;A;C	285,1;288;290	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2054	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1905	134.7	1	SNP	p	G45D	0	.	.	133	135	GGC	764	766	GGC	220;220;220	G;G;C	220;220;220	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1272	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1304	120.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5662	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3466	203.3	1	SNP	p	D86N	0	.	.	256	258	GAC	938	940	GAC	245;243;245	G;A;C	245;243;245	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5662	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3466	203.3	1	SNP	p	S87R	0	.	.	259	261	AGT	941	943	AGT	247;246;246	A;G;T,C	247;246;245,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5662	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3466	203.3	1	SNP	p	S87I	0	.	.	259	261	AGT	941	943	AGT	247;246;246	A;G;T,C	247;246;245,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5662	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3466	203.3	1	SNP	p	S87W	0	.	.	259	261	AGT	941	943	AGT	247;246;246	A;G;T,C	247;246;245,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5662	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3466	203.3	1	SNP	p	S88P	0	.	.	262	264	TCC	944	946	TCC	248;244;246	T;C;C	248;244;246	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4482	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3182	175.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1810	1812	GGC	219;220;220	G;G,T;C	219;219,1;220	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1539	1541	GCA	264;265;265	G,T,C;C;A	262,1,1;265;265	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1542	1544	ATC	267;265;263	A,G;T,G,C;C	266,1;263,1,1;263	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1554	1556	GTG	259;259;259	G;T;G,A	259;259;258,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1554	1556	GTG	259;259;259	G;T;G,A	259;259;258,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2058	2060	ACC	248;246;246	A;C,G;C,G	248;245,1;245,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2112	2114	GCG	252;249;249	G;C;G,C	252;249;247,2	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2112	2114	GCG	252;249;249	G;C;G,C	252;249;247,2	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2235	2237	GGC	236;240;240	G;G,A;C	236;239,1;240	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2244	2246	GGC	246;247;249	G,C;G;C	245,1;247;249	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4406	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2950	186.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2262	2264	CCG	263;262;261	C,G;C;G	262,1;262;261	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6164	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3714	207.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2692	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2269	147.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	769	769	C	212	C,T,G	210,1,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	S271T	NONSYN	811	813	TCG	53	55	ACT	77;77;77	A;C;T	76;76;76	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	59	61	GAT	77;77;77	G;A;T	76;76;76	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	D276N	NONSYN	826	828	GAT	68	70	AAC	78;78;78	A;A;C	77;77;77	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	N277H	NONSYN	829	831	AAC	71	73	CAC	78;78;79	C;A;C	77;77;78	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	R307E	NONSYN	919	921	AGA	161	163	GAA	5;5;5	G;A;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	5;5;5	G;A;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	5;5;5	A;T;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	5;5;4	T;C;G	5;5;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	4;3;3	A;G;C	4;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	370	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	229	44.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	A26T	NONSYN	76	78	GCC	569	571	ACC	281;284;283	A;C;C	281;284;283	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	D41K	NONSYN	121	123	GAC	614	616	AAA	303;303;305	A;A;A	303;303;305	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	A109V	NONSYN	325	327	GCC	818	820	GTC	277;276;276	G;T,G;C	277;275,1;276	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	884	886	TAT	266;268;267	T;A;T	266;268;267	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	N134E	NONSYN	400	402	AAT	893	895	GAG	255;254;253	G,A;A;G	254,1;254;253	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	V135L	NONSYN	403	405	GTG	896	898	CTT	251;254;250	C;T,C;T,C	251;253,1;249,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	G140K	NONSYN	418	420	GGA	911	913	AAA	260;263;261	A;A;A	260;263;261	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	K143G	NONSYN	427	429	AAA	920	922	GGA	258;260;258	G;G;A	258;260;258	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	944	946	GCA	257;260;259	G;C;A	257;260;259	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	D171G	NONSYN	511	513	GAC	1004	1006	GGT	287;288;285	G,A,C;G,T;T	284,2,1;286,1;285	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1052	1054	CGA	291;290;290	C,A;G;A,C	289,1;290;289,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	Y211_E212insL	INS	631	631	T	1124	1124	T	266	T	266	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1130	1132	GAT	259;258;256	G;A;T	259;258;256	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	H213D	NONSYN	637	639	CAT	1133	1135	GAT	252;254;253	G;A;T	252;254;253	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3186	porB1b	1047	1047	96.11	porB1b.l15.c17.ctg.1	1796	220.4	0	.	p	.	0	Q214fs	FSHIFT	640	640	C	1136	1136	C	253	C	253	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11472	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5262	272.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2209	2211	AAT	327;322;327	A;A;T	327;322;327	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1750	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1433	151.6	1	SNP	p	V57M	1	.	.	169	171	ATG	702	704	ATG	308;306;313	A;T;G,A	308;306;312,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
